Posted inComunicati
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange…









